文献速递妇科

过继性T细胞疗法治疗卵巢癌

Adoptive T cell therapy for ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2024-04-10

卵巢癌多数肿瘤在化疗和DNA修复抑制剂等标准治疗后复发,亟需替代疗法。卵巢癌具免疫原性,肿瘤浸润淋巴细胞(TILs)尤其T细胞积累与更好预后相关。本文综述通过过继性细胞疗法(ACT)被动输入T细胞的多种策略,包括树突状细胞疫苗体内诱导或体外致敏T细胞、利用自体TILs、以及外周血T细胞经基因修饰表达肿瘤抗原特异性T细胞受体(TCR)或嵌合抗原受体(CAR),并探讨推进ACT治疗卵巢癌的策略。

要点

  • 卵巢癌患者通常对化疗和DNA修复抑制剂等标准治疗有反应,但多数肿瘤复发。
  • 卵巢癌具免疫原性,肿瘤浸润淋巴细胞(TILs)尤其T细胞积累与更好患者结局相关。
  • ACT策略包括树突状细胞疫苗、自体TILs及基因修饰表达TCR或CAR的外周血T细胞。

核心结论

  • 通过被动输入T细胞的过继性细胞疗法(ACT)是治疗卵巢癌的有前景的治疗选择。

研究设计与样本

  • 综述,检索范围未报告。

主要发现

  • 卵巢癌患者通常对化疗和DNA修复抑制剂等标准治疗有反应,但多数肿瘤复发。
  • 卵巢癌具免疫原性,肿瘤浸润淋巴细胞(TILs)尤其T细胞积累与更好患者结局相关。
  • 树突状细胞癌症疫苗可体内给药诱导或增强针对肿瘤抗原的T细胞反应,或体外致敏T细胞后制备输注。
  • ACT方案可利用从患者肿瘤分离的天然肿瘤反应性T细胞(TILs),其组成和抗原特异性异质,具患者特异性癌症识别。
  • T细胞可来源于外周血,包括经基因修饰表达肿瘤抗原特异性TCR或CAR以重定向特异性并增强抗肿瘤活性的T细胞。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although ovarian cancer patients typically respond to standard of care therapies, including chemotherapy and DNA repair inhibitors, the majority of tumors recur highlighting the need for alternative therapies. Ovarian cancer is an immunogenic cancer in which the accumulation of tumor infiltrating lymphocytes (TILs), particularly T cells, is associated with better patient outcome. Thus, harnessing the immune system through passive administration of T cells, a process called adoptive cell therapy (ACT), is a promising therapeutic option for the treatment of ovarian cancer. There are multiple routes by which tumor-specific T cell products can be generated. Dendritic cell cancer vaccines can be administered to the patients to induce or bolster T cell responses against tumor antigens or be utilized ex vivo to prime T cells against tumor antigens; these T cells can then be prepared for infusion. ACT protocols can also utilize naturally-occurring tumor-reactive T cells isolated from a patient tumor, known as TILs, as these cells often are heterogeneous in composition and antigen specificity with patient-specific cancer recognition. Alternatively, T cells may be sourced from the peripheral blood, including those that are genetically modified to express a tumor antigen-specific T cell receptor (TCR) or chimeric antigen receptor (CAR) to redirect their specificity and promote their activity against tumor cells expressing the target tumor antigen. Here, we review current ACT strategies for ovarian cancer and provide insights into advancing ACT therapy strategies for the treatment of ovarian cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Gitto SB, Ihewulezi CJN, Powell DJ, et al. Adoptive T cell therapy for ovarian cancer. Gynecol Oncol. 2024. PMID: 38603955. doi:10.1016/j.ygyno.2024.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。